Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, prospective, noninterventional program analysing the safety and effectiveness of edoxaban

X
Trial Profile

A multicentre, prospective, noninterventional program analysing the safety and effectiveness of edoxaban

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms global ETNA-AF
  • Most Recent Events

    • 28 Aug 2023 Results assessing Persistence to edoxaban treatment in patients with atrial fibrillation using 2-year data from this study presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
    • 28 Aug 2023 Results (n=26,580 ) assessing clinical parameters associated with cardiovascular events in patients with AF receiving adequate anticoagulation presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
    • 28 Aug 2022 According to a Daiichi Sankyo media release, two-year effectiveness and safety outcomes in edoxaban-treated patients with and without a history of major bleeding, real-world effectiveness and safety of edoxaban in patients with and without a history of heart failure, and those with and without a history of ischaemic stroke from the program were presented at The European Society of Cardiology Congress 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top